illumicell AI names Trevor Slattery CTO

illumicell AI appointed TechMed cybersecurity and AI executive Trevor Slattery as chief technology officer on June 24, 2026, to help build the technical and security foundation for its machine-readable biology platform. The move comes as the Boston company pushes from male fertility diagnostics toward broader clinical applications.

Why it matters: - illumicell AI is trying to turn biological samples into machine-readable data, and the CTO hire adds leadership for security, scale and regulatory readiness. - The appointment comes as the company’s first application targets male fertility diagnostics, a space where manual workflows and operator variability still shape clinical decisions. - A stronger technical foundation could matter as the platform expands beyond semen analysis into other biofluids and clinical uses.

What happened: - illumicell AI appointed Trevor Slattery as chief technology officer on June 24, 2026. - Slattery will work with the engineering and product teams to shape technical architecture and build a secure, scalable base for the platform. - The company is based in Boston.

The details: - Slattery is a technology executive with experience in AI, machine learning and cybersecurity in regulated medical technology. - He has held C-suite roles in technology and operations, plus senior sales leadership roles. - His background spans product development, engineering, compliance and commercialization. - Across prior roles, Slattery supported work tied to more than 250 FDA submissions across 510(k), De Novo, PMA, HDE and IDE pathways. - His technical experience includes penetration testing, threat modeling, machine-learning pipelines, cloud infrastructure and FDA-regulated data practices. - Before joining illumicell AI, Slattery held senior leadership roles at Blue Goat Cyber, including CTO, vice president of sales and COO. - Slattery has also co-hosted a medical device cybersecurity podcast and speaks at industry conferences. - illumicell AI is developing proprietary 3D imaging and AI to make biological samples machine-readable. - The platform is designed to scan and analyze more of each sample at once, capture cellular movement and transform biofluids into structured diagnostic data. - The company’s first indication is male fertility diagnostics, with a focus on low-count semen samples where existing automated analyzers can fail and clinical decisions are especially sensitive. - The broader platform is intended to extend across biofluids including immune cells, urine and cerebrospinal fluid.

Between the lines: - The hire signals that illumicell AI is treating cybersecurity and regulatory design as core product requirements, not add-ons. - Michel Bielecki said he first met Slattery at a MedTech conference in Shanghai, where Slattery described himself as a white hat hacker. - Bielecki said Slattery will help the company execute efficiently while building the technical and regulatory foundation for the broader platform. - Co-founder and Chief Strategy Officer Jeyla Sadikova said the company is building imaging systems for a future where biology can be read objectively by machines.

What's next: - Slattery is expected to help the company harden its architecture as illumicell AI develops toward broader clinical indications. - The platform’s near-term focus remains male fertility diagnostics, while the longer-term plan is expansion across additional sample types and uses. - illumicell AI is likely to keep emphasizing regulation-ready infrastructure as it scales.

The bottom line: - illumicell AI is pairing its machine-readable biology ambitions with a CTO hire rooted in cybersecurity, FDA-regulated systems and product scale.